Recent advancements in blood-based AD diagnostics have brought exciting potential tests to the field that involve measurements of the Aβ42/Aβ40 concentration ratio, a conformational variant of U-p53 and detection of phosphorylated versions of tau proteins, such as pTau181 and pTau217, and neurofilament light (NfL) [22, 26–34]. Here, MAPT is linked to Alzheimer disease.